Saturday 17 October 2026 Export RCEL’s income statement to Excel — free account

Avita Medical Inc.

Avita Medical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $71.6 million, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 17.8%, EPS grew 33.8%, free cash flow grew 66.5% and total debt rose 10.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

13.04 0.37 −2.76%

Follow RCEL

Alert me

Market cap: $333.1M
P/E: 0.0×
Fwd P/E: −3.6×
Dividend yield: —
F-score: 3/9
Altman Z: −11.96
Beneish M: −4.09
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.23

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	1	—	—	2	5	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 333.10

Revenue 75.63

Net Income (43.08)

Free Cash Flow (25.25)

Net Debt 35.52

Current Ratio 0.41

Debt/Equity (1.68)

P/E ratio 0.00

Fwd P/E (3.63)

P/S ratio 0.27

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 45.66%

Next Y EPS Growth 59.31%

Next Y revenue growth 19.28%

Next 5Y EPS Growth 68.77%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 39.63%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	89	36	18	11
Receivables	8	12	9	10
Inventory	6	7	7	5
Other	—	—	—	—
	104	57	35	28

	2023	2024	2025	Q'26
Payables	4	6	9	6
ST’ Debt	—	—	43	47
Other	1	3	3	7
	13	20	63	69

Compound Annual Growth %

	10y	5y	3y
Sales	54.42%	19.63%	27.66%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	19	22	—	—	—
’25	19	18	17	18	72
’24	11	15	20	18	64
’23	11	12	14	14	50
’22	8	8	9	9	34
’21	—	—	7	(12)	29
’21	9	10	—	—	29

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(10)	(3)	—	—	—
’25	(10)	(10)	(5)	(5)	(31)
’24	(21)	(13)	(7)	(8)	(49)
’23	(9)	(9)	(9)	(11)	(38)
’22	(9)	(4)	(3)	(3)	(19)
’21	—	—	(1)	8	(26)
’21	(9)	(4)	—	—	(26)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(10)	(4)	—	—	—
’25	(11)	(11)	(6)	(5)	(33)
’24	(22)	(16)	(11)	(10)	(58)
’23	(9)	(9)	(9)	(11)	(39)
’22	(9)	(4)	(3)	(4)	(20)
’21	—	—	(1)	8	(26)
’21	(9)	(4)	—	—	(27)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(6.95)	(4.98)	—	—	—
’25	(10.56)	(7.52)	(9.29)	(7.51)	(34.88)
’24	(14.55)	(11.95)	(12.47)	(8.81)	(47.79)
’23	(7.32)	(8.23)	(6.86)	(5.52)	(27.92)
’22	(7.59)	(5.01)	(4.47)	(4.26)	(21.33)
’21	—	—	(4.78)	(0.34)	(1.17)
’21	(5.28)	(3.80)	—	—	(23.45)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	6.75	3.75	3.85	5.45	16.87	11.54	4.41	6.32	7.51	3.25	Analyst estimates 2026–2028 Powerpack
	High	12.30	9.30	10.75	49.10	55.35	28.49	12.28	21.70	18.93	14.16
People
People	Employees	26	37	55	—	98	108	126	207	260	226
	Revenue/emp, $m	0.03	0.02	0.00	0.00	0.00	0.00	0.27	0.24	0.25	0.32
Income, $m
Income, $m	Revenue	1	1	1	6	14	29	34	50	64	72
	Gross margin, %	59.92	57.17	57.33	77.97	79.16	79.65	82.45	84.48	85.85	82.13
	EBT	(8)	(9)	(14)	(25)	(42)	(27)	(27)	(35)	(62)	(49)
	EBT margin, %	(1,122.08)	(1,063.75)	(1,493.54)	(458.64)	(294.65)	(90.81)	(77.36)	(70.43)	(96.17)	(67.83)
	Net income	(6)	(9)	(13)	(25)	(42)	(27)	(27)	(35)	(62)	(49)
	Depreciation	0	0	0	0	1	1	1	1	1	2
Per share, $
Per share, $	Revenue	0.15	0.13	0.01	0.02	0.70	1.29	27.54	39.58	49.65	51.41
	Earnings	(1.50)	(1.30)	(0.07)	(0.10)	(2.07)	(1.17)	(21.33)	(27.92)	(47.79)	(34.88)
	Cash flow	(1.16)	(0.96)	(0.07)	(0.08)	(1.12)	(1.14)	(15.27)	(30.00)	(37.82)	(22.39)
	Capex	(0.01)	0.02	0.00	0.00	0.00	(0.01)	(0.42)	(1.09)	(7.09)	(1.18)
	Free cash flow	(1.17)	(0.94)	(0.07)	(0.08)	(1.12)	(1.15)	(15.69)	(31.09)	(44.91)	(23.57)
	Book value	1.00	0.58	0.08	0.08	3.57	5.10	67.79	38.72	3.48	(11.95)
	Shares, m	5	7	187	253	20	23	1	1	1	1
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	0.00	0.00	0.00	1.12	1.07	0.23	0.34	0.26	0.07
	P/B	0.00	0.00	0.00	0.50	0.34	0.14	0.10	0.35	3.68	0.00
	EV/Sales	0.00	0.00	0.00	0.00	(2.11)	(4.98)	(2.04)	(0.62)	0.37	0.99
	EV/FCF	0.22	0.14	0.65	2.34	2.64	12.34	3.57	0.79	(0.41)	(2.15)
Cash, $m
Cash, $m	Operating cash flow	(6)	(6)	(13)	(20)	(23)	(26)	(19)	(38)	(49)	(31)
	Capex	0	0	0	(1)	(1)	0	(1)	(1)	(9)	(2)
	Free cash flow	(6)	(6)	(13)	(20)	(23)	(26)	(20)	(39)	(58)	(33)
Balance, $m
Balance, $m	Working capital	5	4	14	20	71	114	77	91	37	(27)
	Total debt	—	—	0	0	2	2	1	40	42	43
	Net debt	(4)	(3)	(11)	(20)	(71)	(109)	(78)	(49)	6	25
	Shareholders’ equity	5	4	14	21	72	116	85	49	4	(17)
Returns, %
Returns, %	ROA	(138.32)	(144.05)	(73.46)	(96.61)	(50.97)	(21.18)	(23.83)	(33.71)	(64.64)	(71.40)
	ROIC	(358.28)	(589.65)	0.00	0.00	0.00	(142.98)	(263.35)	0.00	(324.79)	(334.18)
	ROE	(175.68)	(196.03)	(88.99)	(117.92)	(58.05)	(22.98)	(26.61)	(52.89)	(230.96)	799.72

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
OFIX ORTHOFIX MEDICAL INC.	$390.6M	— (loss-making)	— (loss-making)	+3.85% (above 0%: growing)	n/m	−516.58% (below 0%: shrinking)	70.97%	(3.86%)	Compare
SI Shoulder Innovations, Inc.	$382.4M	— (loss-making)	— (loss-making)	+55.95% (above 0%: growing)	n/m	−52.42% (below 0%: shrinking)	78.26%	(58.43%)	Compare
VMD Viemed Healthcare, Inc.	$371.4M	24.9×	21.9×	+23.85% (above 0%: growing)	−12.50% (below 0%: shrinking)	−18.15% (below 0%: shrinking)	57.68%	6.39%	Compare
CV CapsoVision, Inc.	$343.2M	2.1×	— (loss-making)	+9.89% (above 0%: growing)	n/m	−84.44% (below 0%: shrinking)	51.36%	(208.07%)	Compare
RCEL Avita Medical Inc.	$333.1M	— (loss-making)	— (loss-making)	+17.83% (above 0%: growing)	n/m	+66.52% (above 0%: growing)	81.87%	(28.42%)
CLPT ClearPoint Neuro, Inc.	$294.1M	— (loss-making)	— (loss-making)	+18.07% (above 0%: growing)	n/m	−173.51% (below 0%: shrinking)	61.67%	(94.15%)	Compare
QSI Quantum-Si Incorporated	$286.7M	— (loss-making)	— (loss-making)	−41.79% (below 0%: shrinking)	n/m	+9.75% (above 0%: growing)	50.00%	(7,450.29%)	Compare
INFU InfuSystems Holdings, Inc.	$277.2M	31.7×	21.7×	+2.59% (above 0%: growing)	+33.33% (above 0%: growing)	−66.54% (below 0%: shrinking)	57.98%	11.24%	Compare
TMCI Treace Medical Concepts, Inc.	$267.9M	— (loss-making)	— (loss-making)	−4.24% (below 0%: shrinking)	n/m	+11.74% (above 0%: growing)	78.47%	(32.96%)	Compare
Median of peers	$318.6M	24.9×	—	+6.87%	—	−59.48%	59.83%	(45.69%)

All 149 Medical Devices stocks →

Avita Medical Inc. (RCEL) key facts

Strength: Avita Medical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $71.6 million, up 11.5% from fiscal 2024.
Avita Medical Inc. (RCEL) is a Medical Devices company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, RCEL traded at $13.04, a market capitalization of $333.1 million.
Return on equity was 799.7% and debt-to-equity -1.68.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −11.96 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.